Denmark's BioPorto Q1 revenue rises 23%, EBITDA loss narrows

BioPorto A/S

21/05/2026 08:05

Overview

Denmark diagnostics firm's Q1 revenue rose 23% yr/yr, driven by US neutrophil gelatinase-associated lipocalin (NGAL) product sales

Adjusted EBITDA loss for Q1 narrowed 36% yr/yr, in line with company expectations

Company completed antibody business divestment in April, strengthening financial position

Outlook

BioPorto maintains 2026 guidance: total revenue DKK 38-48 mln, NGAL revenue DKK 33-42 mln

Company expects to onboard at least 60 US hospitals for NGAL products by end 2026

BioPorto says updated KDIGO guidelines support commercialization of NGAL products in coming periods

Result Drivers

US NGAL RUO SALES - Co said Q1 revenue growth was mainly driven by increased US NGAL Research Use Only sales

NEW US HOSPITALS - Four new US hospitals onboarded for NGAL RUO, supporting broader market penetration

DISTRIBUTOR SALES - Sales through NGAL distributors contributed to Q1 revenue growth, though co said distributor revenue can be uneven

Company press release: ID:nGNE2G4Xfg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
DKK 9.4 mln
Q1 Adjusted EBITDA
-DKK 17.9 mln


Analyst Coverage

Wall Street's median 12-month price target for Bioporto A/S is DKK1.75, about 50.2% above its May 20 closing price of DKK1.17

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)